Related references
Note: Only part of the references are listed.The significance of FOXP1 in diffuse large B-cell lymphoma
Duncan M. Gascoyne et al.
LEUKEMIA & LYMPHOMA (2017)
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies
Luciano J. Costa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
Ryan D. Morin et al.
CLINICAL CANCER RESEARCH (2016)
dbNSFP v3.0: A One-Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site SNVs
Xiaoming Liu et al.
HUMAN MUTATION (2016)
Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis
D. Juskevicius et al.
LEUKEMIA (2016)
Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
Guoqi Song et al.
ONCOTARGETS AND THERAPY (2016)
Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment
Felicitas Hitz et al.
ANNALS OF HEMATOLOGY (2015)
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
Christoph Mamot et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study
Alexandar Tzankov et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
Alessandro Pastore et al.
LANCET ONCOLOGY (2015)
The Genetic Landscape of Diffuse Large B-Cell Lymphoma
Laura Pasqualucci et al.
SEMINARS IN HEMATOLOGY (2015)
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
Chengliang Dong et al.
HUMAN MOLECULAR GENETICS (2015)
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2015)
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou et al.
BLOOD (2014)
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
David W. Scott et al.
BLOOD (2014)
False Positives in Multiplex PCR-Based Next-Generation Sequencing Have Unique Signatures
Chad M. McCall et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2014)
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
Alexandar Tzankov et al.
MODERN PATHOLOGY (2014)
MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma
C. Fernandez-Rodriguez et al.
LEUKEMIA (2014)
Analysis of FOXO1 mutations in diffuse large B-cell lymphoma
Diane L. Trinh et al.
BLOOD (2013)
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing
Ryan D. Morin et al.
BLOOD (2013)
Genetic heterogeneity of diffuse large B-cell lymphoma
Jenny Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Zijun Y. Xu-Monette et al.
BLOOD (2012)
CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia
A. Inthal et al.
LEUKEMIA (2012)
CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab
K. Miyazaki et al.
ANNALS OF ONCOLOGY (2011)
The molecular pathogenesis of primary mediastinal large B-cell lymphoma
Christian Steidl et al.
BLOOD (2011)
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium
Gilles Salles et al.
BLOOD (2011)
Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
Paul N. Meyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
CREBBP mutations in relapsed acute lymphoblastic leukaemia
Charles G. Mullighan et al.
NATURE (2011)
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Laura Pasqualucci et al.
NATURE (2011)
Analysis of the coding genome of diffuse large B-cell lymphoma
Laura Pasqualucci et al.
NATURE GENETICS (2011)
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Jonathan W. Friedberg
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2011)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494
Jane N. Winter et al.
CLINICAL CANCER RESEARCH (2010)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Laurie H. Sehn et al.
BLOOD (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2
S Kamizono et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
